U.S. markets close in 4 hours 33 minutes

  • S&P 500

    4,246.96
    +0.37 (+0.01%)
     

  • Dow 30

    34,281.06
    -18.27 (-0.05%)
     

  • Nasdaq

    14,101.38
    +28.52 (+0.20%)
     

  • Russell 2000

    2,309.09
    -10.98 (-0.47%)
     

  • Crude Oil

    72.71
    +0.59 (+0.82%)
     

  • Gold

    1,858.70
    +2.30 (+0.12%)
     

  • Silver

    27.88
    +0.18 (+0.66%)
     

  • EUR/USD

    1.2123
    -0.0010 (-0.08%)
     

  • 10-Yr Bond

    1.4910
    -0.0080 (-0.53%)
     

  • GBP/USD

    1.4107
    +0.0025 (+0.18%)
     

  • USD/JPY

    109.9380
    -0.0960 (-0.09%)
     

  • BTC-USD

    38,742.02
    -1,217.18 (-3.05%)
     

  • CMC Crypto 200

    959.57
    -32.90 (-3.32%)
     

  • FTSE 100

    7,196.76
    +24.28 (+0.34%)
     

  • Nikkei 225

    29,291.01
    -150.29 (-0.51%)
     

Kindred Biosciences Stock Jumps On $440M Elanco Animal Buyout Deal

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
Vandana Singh
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

  • Elanco Animal Health Incorporated (NYSE: ELAN) has agreed to acquire Kindred Biosciences Inc (NASDAQ: KIN) for $9.25 per share, or approximately $440 million.

  • The price represents a premium of 52% based on the 30-day average.

  • Elanco will fund the acquisition with pre-payable debt and expects to extend its leverage objective of under three times net leverage to Adjusted EBITDA by three months, from the end of 2023 to the end of Q1 of 2024.

  • KindredBio brings three potential dermatology products expected to launch through 2025 and several additional R&D programs.

  • The combination will add approximately $100 million to Elanco's previously stated innovation revenue expectation of $500 million to $600 million by 2025, with significant opportunity beyond the period.

  • The acquisition agreement builds on Elanco's existing relationship with KindredBio, which began with licensing the global commercial rights of KindredBio's late-stage treatment for canine parvovirus.

  • Transaction and operating costs will be slightly dilutive to Elanco's reported and adjusted EPS in 2021. The impact is expected to be concentrated in the fourth quarter and slightly dilutive to the full year 2022.

  • Elanco also reaffirmed the second quarter 2021 revenue guidance of $1,225 million to $1,255 million and full-year 2021 revenue guidance of $4,670 million to $4,710 million.

  • Elanco will host a conference call today at 8:00 am E.T.

  • Price Action: KIN shares are up 44.6% at $9.17 during the premarket session on the last check Wednesday, while ELAN shares closed at $34.81 on Tuesday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Recommended Stories

  • Elanco Strikes Deal to Better Compete With Rival Zoetis in Pet Dermatology

    Elanco Animal Health said it struck a $440 million deal to acquire Kindred Biosciences, a move that will bolster its drug pipeline, particularly the fast-growing pet dermatology segment.

  • Citi CFO Mason warns of mixed year for bank even as recovery continues

    The bank, however, does not expect a sizeable uptick in corporate loan growth for the rest of the year, Mason warned, even as consumer borrowing is seen picking up in the second half. "Given the liquidity that's in the market and all the debt issuance activity that we saw last year, I'm not expecting corporate loan growth in the balance of the year," Mason said. Mason also said he expects to hear back over the next month from potential buyers for its consumer operations in the Asia and markets in Europe, the Middle East and Africa the bank is exiting.

  • AMC poised to take over Pacific movie theaters at the Grove and Americana

    Pacific movie theaters at the Grove in Los Angeles and at the Americana in Glendale would add to AMC's Southern California portfolio.

  • Lumber Set to Snap 8-Day Slump Ahead of U.S. Housing Report

    (Bloomberg) -- U.S. lumber futures are set to snap an eight-session losing streak as traders who bet on price declines cashed in ahead of Wednesday’s U.S. housing starts report.Traders betting against lumber sold off short positions in futures contracts on expectations that the key housing report will show a steady number of homes were built in the U.S. in May, said Brian Leonard, an analyst with RCM Alternatives in Chicago.“We are $800 from the highs, so a steady report would bring shorts out o

  • Why These 24 Controversial S&P 500 Stocks Could Be Worth Buying

    Barron's screened for the 24 S&P 500 stocks that divide Wall Street analysts the most. It was no shock that Tesla was on the list, but some names came as a surprise.

  • Top Pharmaceutical Stocks for Q3 2021

    These are the pharmaceutical stocks with the best value, fastest growth, and most momentum for Q3 2021.

  • Why AMC and Torchlight Energy Stocks Popped Today -- but Petco Stock Dropped

    Shares of AMC Entertainment (NYSE: AMC) and especially Torchlight Energy (NASDAQ: TRCH) are going "to the moon" today, having risen 11% and 44% (!) respectively in 11 a.m. EDT trading. In contrast, it looks as if Petco Health and Wellness (NASDAQ: WOOF) stock is in the doghouse -- down 8.4%. There's no particular substantive news that could explain Torchlight's astounding 44% rally in the first 90 minutes of trading today.

  • Cruise stocks upgraded, Oracle lowers guidance, ARK Invest buys DraftKings dip

    Myles Udland, Brian Sozzi, and Julie Hyman break down Wednesday’s early market movers which include: Oracle’s stock taking a dip after announcing lower quarterly revenue guidance than expected, Wolfe Research upgrading cruise industry stocks as the firm says all signs are pointing to a strong restart in the industry, and Ark Invest buying $42 million in shares of DraftKings after short-seller report.

  • The Very Good Food Company Announces $15 Million Bought Deal Offering

    The Very Good Food Company Inc. (TSXV: VERY.V) (OTCQB: VRYYF) (FSE: 0SI) ("VERY GOOD" or the "Company"), a leading plant-based food technology company, is pleased to announce that it has entered into an agreement with Canaccord Genuity Corp. (the "Underwriter"), acting as lead underwriter and sole bookrunner, pursuant to which the Underwriter has agreed to purchase, on a bought deal basis, an aggregate of 4,055,000 units of the Company (the "Units") at a price of $3.70 per Unit (the "Issue Price

  • Why COVID Vaccine Stocks Dynavax, Novavax, and Vaxart Are Sinking Today

    Dynavax Technologies (NASDAQ: DVAX) stock was down 6.3% as of 11:26 a.m. EDT, while shares of Novavax (NASDAQ: NVAX) and Vaxart (NASDAQ: VXRT) were falling 7.8% and 10.6%, respectively. The declines for the biotech stocks appear to merely be run-of-the-mill volatility on a day when the overall stock market was down. Sales of its Heplisav-B hepatitis B vaccine were negatively impacted by the COVID-19 pandemic.

  • First Look: Solid Power, a Ford-Backed QuantumScape Rival, Will Go Public via SPAC

    Many investors have been overwhelmed by the number of SPAC deals in the electric-vehicle space over the last year, and some have soured on the space now that a couple of last year's darlings have turned out to be, well, less than they seemed. Colorado-based Solid Power, founded in 2012, is one of several companies working to develop so-called solid-state batteries, which omit the liquid electrolyte used in the lithium-ion batteries that power most electric vehicles today.

  • Cristiano Ronaldo just made Coca-Cola stock interesting

    Soccer great Cristiano Ronaldo sends a jolt to Coke's investors.

  • 10 Best Steel Stocks to Buy Amid Upcoming Infrastructure, Construction Boom

    In this article we will take a look at the 10 best steel stocks to buy amid upcoming infrastructure, construction boom. You can skip our detailed analysis of these companies, and go directly to the 5 Best Steel Stocks to Buy Amid Upcoming Infrastructure, Construction Boom. Steel prices are soaring amid a rising demand as […]

  • VIAVI Announces Proposal to Acquire EXFO at US$7.50 per Share

    (NASDAQ: VIAV) Viavi Solutions Inc. ("VIAVI") announced today that it has submitted a proposal (the "Proposal") to the board of directors of EXFO Inc. (TSX: EXF) (NASDAQ: EXFO) ("EXFO") to acquire all of the outstanding subordinate voting shares and multiple voting shares of EXFO at a price of US$7.50 (C$9.14 at yesterday's exchange rate) in cash per share. The Proposal values EXFO at approximately US$430 million (C$524 million at yesterday's exchange rate) on an undiluted basis, and represents

  • Should Investors Buy Just Eat Takeaway After It Devours Grubhub?

    Just Eat Takeaway's (OTC: GRUB) $7.3 billion takeover of Grubhub, which was announced a year ago, finally closed on June 15. Grubhub's investors received 0.671 shares of the new American depositary receipts for each of their original shares, and the merged company will become one of the world's largest third-party food delivery platforms outside of China. Grubhub's investors might be wondering if they should sell their new shares or put some faith in the new company.

  • Do Hedge Funds Love Orphazyme A/S (ORPH)?

    The Insider Monkey team has completed processing the quarterly 13F filings for the March quarter submitted by the hedge funds and other money managers included in our extensive database. Most hedge fund investors experienced strong gains on the back of a strong market performance, which certainly propelled them to adjust their equity holdings so as […]

  • SAGE Announces Positive Results for Zuranolone; Shares Plunge 19.3%

    Biopharmaceutical company Sage Therapeutics, Inc. (SAGE) and Biogen Inc. (BIIB), a pioneer in neuroscience, together announced positive results for the Zuranolone drug, which is being evaluated for the treatment of Major Depressive Disorder (MDD). However, Shares of SAGE plunged 19.3% to close at $58.80 on June 15, as the findings of the WATERFALL study fell short of investors’ expectations. Sage is a clinical-stage biopharmaceutical company engaged in the development and commercialization of no

  • Is Aethlon Medical, Inc. (AEMD) A Good Stock To Buy?

    In this article we will check out the progression of hedge fund sentiment towards Aethlon Medical, Inc. (NASDAQ:AEMD) and determine whether it is a good investment right now. We at Insider Monkey like to examine what billionaires and hedge funds think of a company before spending days of research on it. Given their 2 and […]

  • The Fed Should Talk About Tapering. Here’s What Could Happen to the Stock Market.

    The Fed has limited margin for error in what the central bank says about its current easy-money policy. Any miscues on messaging could be costly to stock investors.

  • My Top Growth Stock to Buy in June

    Marvell Technology Group (NASDAQ: MRVL) looked like an enticing bet going into its first-quarter fiscal 2022 earnings report thanks to a bunch of powerful catalysts, and the company didn't disappoint. The chipmaker bested Wall Street's estimates as its top and bottom lines shot up remarkably, while the outlook was solid enough to send the stock higher after the earnings report. Robust demand from several fast-growing end markets gave Marvell a nice boost during the quarter, a trend that's likely to continue for a long time to come.